<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02412163</url>
  </required_header>
  <id_info>
    <org_study_id>PR0123</org_study_id>
    <nct_id>NCT02412163</nct_id>
  </id_info>
  <brief_title>Ellipse Intramedullary Nail High Tibial Osteotomy Study</brief_title>
  <acronym>IM HTO</acronym>
  <official_title>A Multicenter Study of Patients Treated With the Ellipse Technologies Intramedullary High Tibial Osteotomy (IM HTO) Nail System for Osteoarthritis and Varus Malalignment of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ellipse Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ellipse Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study further evaluates the safety profile and efficacy of the Ellipse IM HTO Nail&#xD;
      system in subjects with osteoarthritis and varus malalignment of the knee. All subjects will&#xD;
      receive treatment with the Ellipse IM HTO Nail System and followed for six months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Ellipse IM HTO Nail is intended for open wedge proximal tibial osteotomies. The Ellipse&#xD;
      IM HTO Nail is an intramedullary nail that operates on the principles of distraction&#xD;
      osteogenesis.&#xD;
&#xD;
      The Ellipse IM HTO Nail is used in valgizing HTO procedures to correct varus malalignment.&#xD;
      The Ellipse IM HTO Nail is surgically placed in the intramedullary canal of the tibia. It is&#xD;
      lengthened telescopically using the non-invasive external remote control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Weight-Bearing Line at Final Correction within ±5, 10, and 15% of Baseline Target</measure>
    <time_frame>Pre-Op, Week 6 (Considered the Final Correction Visit unless additional visits are required)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Difference in Weight-Bearing Line Final Target versus Actual at Final Consolidation</measure>
    <time_frame>Week 6 (Considered the Final Correction Visit unless additional visits are required), Month 6 (Considered the Final Consolidation Visit unless additional visits are required)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Difference in Weight-Bearing Line Baseline Target versus Final Target</measure>
    <time_frame>Pre-Op, Month 6 (Considered the Final Consolidation Visit unless additional visits are required)</time_frame>
    <description>Baseline Target versus Final Target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hip-Knee-Ankle Angle Baseline versus Final Correction</measure>
    <time_frame>Pre-Op, Week 6 (Considered the Final Correction Visit unless additional visits are required)</time_frame>
    <description>Baseline versus Final Correction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hip-Knee-Ankle Angle Baseline versus Final Consolidation</measure>
    <time_frame>Pre-Op, Month 6 (Considered the Final Consolidation Visit unless additional visits are required)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tibial Slope Angle Baseline versus Final Correction</measure>
    <time_frame>Pre-Op, Week 6 (Considered the Final Correction Visit unless additional visits are required)</time_frame>
    <description>Baseline versus Final Correction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tibial Slope Angle Baseline versus Final Consolidation</measure>
    <time_frame>Pre-Op, Month 6 (Considered the Final Consolidation Visit unless additional visits are required)</time_frame>
    <description>Baseline versus Final Consolidation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Full Weight-Bearing</measure>
    <time_frame>Week 2, Week 4, Week 6, Month 3, Month 6</time_frame>
    <description>Amount of time required until a patient is allowed to put 100% of their body weight on the leg.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>Pre-Op, Operative, Week 2, Week 4, Week 6, Month 3, Month 6</time_frame>
    <description>Incidence of Serious Adverse Events upon enrollment into the study</description>
  </other_outcome>
  <other_outcome>
    <measure>Unanticipated Adverse Device Effects</measure>
    <time_frame>Pre-Op, Operative, Week 2, Week 4, Week 6, Month 3, Month 6</time_frame>
    <description>Incidence of Unanticipated Adverse Effects upon enrollment into the study</description>
  </other_outcome>
  <other_outcome>
    <measure>Non-Serious Adverse Events</measure>
    <time_frame>Pre-Op, Operative, Week 2, Week 4, Week 6, Month 3, Month 6</time_frame>
    <description>Incidence of Non-Serious Adverse Events upon enrollment into the study</description>
  </other_outcome>
  <other_outcome>
    <measure>Secondary Surgical Procedures</measure>
    <time_frame>Pre-Op, Operative, Week 2, Week 4, Week 6, Month 3, Month 6</time_frame>
    <description>Incidence of Secondary Surgical Procedures upon enrollment into the study</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">41</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Varus Malalignment</condition>
  <arm_group>
    <arm_group_label>IM HTO Nail</arm_group_label>
    <description>Implant with the Ellipse IM HTO Nail</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ellipse IM HTO Nail</intervention_name>
    <arm_group_label>IM HTO Nail</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who meet the protocol eligibility criteria including standing varus malalignment&#xD;
        in the limb presenting with osteoarthritis of the knee.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient has standing varus malalignment benefitting from high tibial osteotomy&#xD;
             correction&#xD;
&#xD;
          2. Patient is diagnosed with current osteoarthritis of the knee&#xD;
&#xD;
          3. Patient is eighteen years of age or greater&#xD;
&#xD;
          4. Patient is a candidate to be implanted with an Ellipse IM HTO System&#xD;
&#xD;
          5. If female of childbearing potential, patient presents with a negative pregnancy test&#xD;
             and agrees to employ adequate birth control measures for the duration of the study&#xD;
&#xD;
          6. Patient understands and accepts the obligation to comply with the required follow-up&#xD;
             visits and is logistically able to meet all study requirements&#xD;
&#xD;
          7. Patient signs informed consent for the use of their personal private data&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient declines to sign informed consent for the use of their personal private data&#xD;
&#xD;
          2. Varus deformity greater than 10°&#xD;
&#xD;
          3. Flexion contracture greater than 15°&#xD;
&#xD;
          4. Knee flexion under 90°&#xD;
&#xD;
          5. Medial/lateral tibial subluxation over 1 cm&#xD;
&#xD;
          6. Medial bone loss of over 3 mm&#xD;
&#xD;
          7. Inflammatory arthritis&#xD;
&#xD;
          8. Arthritis in the lateral compartment&#xD;
&#xD;
          9. Patella baja&#xD;
&#xD;
         10. Weight over 114 kg&#xD;
&#xD;
         11. Severe patellofemoral symptoms&#xD;
&#xD;
         12. Unaddressed ligamentous instability&#xD;
&#xD;
         13. Fixed flexion contracture&#xD;
&#xD;
         14. Known or suspected osteoporosis or osteopenia based on medical history and&#xD;
             radiographic images&#xD;
&#xD;
         15. Current use of nicotine products.&#xD;
&#xD;
         16. Requires other surgical procedures at the time of the HTO surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark T Dahl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Hochschule</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <zip>9728</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <zip>8025</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Ortopedii I Traumatologii</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zagiel Hospital</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lekmed Hospital</name>
      <address>
        <city>Warsaw</city>
        <zip>01-480</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>District Hospital of Wolomin</name>
      <address>
        <city>Wolomin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bristol NHS Trust</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Cumbria University Hospital</name>
      <address>
        <city>Carlisle</city>
        <zip>CA2 7HY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Aintree</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Southampton</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.ellipse-tech.com</url>
    <description>Sponsor Website</description>
  </link>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>April 1, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

